Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: A cellular electric potential measuring container includes a container body and an electrode substrate, the electrode substrate being attached to a lower end of the container body so as to form a plurality of wells. The container body is made from resin and comprises a plurality of tubular portions whose upper and lower ends are open, each of the tubular portions comprises in an inner cavity a measurement portion tapered toward the lower end and having a measurement hole at the lower end, and further on an inner wall at least two retaining means retaining the measurement portion. The electrode substrate comprises a substrate body, with a plurality of measurement electrodes and a plurality of reference electrodes being disposed on one surface of the substrate body. The container body is attached to the surface of the substrate body on which the measurement electrodes and the reference electrodes are disposed, such that the measurement electrodes are exposed through the measurement holes.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

Abstract: Provided is a platelet-rich plasma separator which can carry out the separation of a platelet-rich plasma with a small number of gamma radiation sterilized instruments and a platelet-rich plasma separation method. The platelet-rich plasma separator comprises a first syringe and a second syringe. The first syringe comprises a first syringe cylinder provided with a first port on which a blood collection needle can be mounted, a first cap detachable from the first port, a first gasket for sealing the first syringe cylinder fluid-tightly, which first gasket is reciprocated within the first syringe cylinder, and a first plunger provided detachably on the first gasket.

Abstract: A container for measuring cellular electric potential after being mounted on an electric potential measuring device is provided comprising a container and an electrode substrate, the electrode substrate being attached to a lower end of the container so as to form a plurality of wells, wherein the container comprises a plurality of cylindrical portions whose upper and lower ends are open, the electrode substrate comprises a substrate and a plurality of measurement electrodes and a plurality of reference electrodes disposed on one surface of the substrate, the measurement electrodes and the reference electrodes at least comprise metal-plated copper wiring, a pair of a measurement electrode and a reference electrode are disposed on a bottom of each well, and the measurement electrodes and the reference electrodes are formed by a pre-plating method.

Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: A display unit having a pivot function and prolonged lives of light sources has been implemented according to the present invention. The display unit includes: a screen that is changeable between a first position and a second position and displays an image; at least one first light source that illuminates the screen in the first position; at least one second light source that illuminates the screen in the second position; and a turn-on control section that controls turning on of the first light source and the second light source according to a position. A display device and an information processing apparatus each provided with the display unit have also been implemented according to the present invention.

Abstract: A container for measuring cellular electric potential after being mounted on an electric potential measuring device is provided comprising a container and an electrode substrate, the electrode substrate being attached to a lower end of the container so as to form a plurality of wells, wherein the container comprises a plurality of cylindrical portions whose upper and lower ends are open, the electrode substrate comprises a substrate and a plurality of measurement electrodes and a plurality of reference electrodes disposed on one surface of the substrate, the measurement electrodes and the reference electrodes at least comprise metal-plated copper wiring, a pair of a measurement electrode and a reference electrode are disposed on a bottom of each well, and the measurement electrodes and the reference electrodes are formed by a pre-plating method.

Abstract: A cellular electric potential measuring container includes a container body and an electrode substrate, the electrode substrate being attached to a lower end of the container body so as to form a plurality of wells. The container body is made from resin and comprises a plurality of tubular portions whose upper and lower ends are open, each of the tubular portions comprises in an inner cavity a measurement portion tapered toward the lower end and having a measurement hole at the lower end, and further on an inner wall at least two retaining means retaining the measurement portion. The electrode substrate comprises a substrate body, with a plurality of measurement electrodes and a plurality of reference electrodes being disposed on one surface of the substrate body. The container body is attached to the surface of the substrate body on which the measurement electrodes and the reference electrodes are disposed, such that the measurement electrodes are exposed through the measurement holes.

Abstract: A cellular electric potential measuring container includes a container body and an electrode substrate, the electrode substrate being attached to a lower end of the container body so as to form a plurality of wells, the cellular electric potential measuring container being for measuring cellular electric potential after being mounted on an electric potential measuring device, wherein the container body comprises: a plurality of tubular portions whose upper and lower ends are open. The electrode substrate includes a substrate body, with a plurality of measurement electrodes and a plurality of reference electrodes being disposed on one surface of the substrate body, and the container body is attached to the surface of the substrate body on which the measurement electrodes and the reference electrodes are disposed, and a method for producing a cellular electric potential measuring container.

Abstract: An object of the invention is providing a highly reflective white material and an LED package capable of reflecting light having a peak at a wavelength of 350 nm through 800 nm with high efficiency. In order to achieve the object, a highly reflective white material of the invention includes a mixed resin of an adamantane resin having an acrylic functional group and a silicone resin; and a curative agent. Thus, the white reflective material is less degraded through UV irradiation and exhibits high reflectance in a low wavelength region.

Abstract: Provided is a platelet-rich plasma separator which can carry out the separation of a platelet-rich plasma with a small number of gamma radiation sterilized instruments and a platelet-rich plasma separation method. The platelet-rich plasma separator comprises a first syringe and a second syringe. The first syringe comprises a first syringe cylinder provided with a first port on which a blood collection needle can be mounted, a first cap detachable from the first port, a first gasket for sealing the first syringe cylinder fluid-tightly, which first gasket is reciprocated within the first syringe cylinder, and a first plunger provided detachably on the first gasket.

Abstract: A multilayer wiring board 1 includes an insulating layer 2, a copper wiring upper layer 3 and a copper wiring lower layer 4 laminated on both surfaces of the insulating layer 2, a through hole 5 pierced through the insulating layer 2 and at least one of the copper wiring layers, and a solder conductor 6 which is filled in the through hole 5 and makes connection and electric continuity between the copper wiring upper layer 3 and the copper wiring lower layer 4, where solder exposed surfaces on which a part of the solder conductor 6 is in contact with the copper wiring upper layer 3 or the copper wiring lower layer 4 and exposed to the outermost surface, and the surfaces of the copper wiring upper layer 3 and the copper wiring lower layer 4 are coated and integrated by plating films 8, and the metal-made plating films 8 are made of a metal having an ionization tendency greater than that of the solder conductor 6.